Published doesn’t mean awarded. Fluff

It is a step in the process

Without publishing, is there a chance for being awarded?

https://patentpc.com/blog/how-long-after-publication-is-a-patent-issued

FWIW

$ENZC BOOM! Covid Patent US National Phase Application has posted! 🔥 pic.twitter.com/XCkehnstG2

— King of Prussia (@ImKingofPrussia) January 11, 2024

Anyone depending on others for their Buy/Sell decisions should not be invested the stock market.

JMHO

Maybe we could request Jerome Powell, and he will print 450 Billion Dollars overnight and more importantly, give it out as a gift.

PPS has been down so much, that may be a 210% UP may elicit some good response. 21% UP does not cut it (as of now).

Yeah, a few consecutive 21% may bring back that latent enthusiasm that has been hibernating since summer of 2023.


SAGA has multiple battles to fight - and they cannot pick and choose. Sincerely does not look good.
There is probably more drama going on between SAGA and GLD than what we are aware of.

Happy New Year !! and hoping for a wonderful 'ENZC-2024'.

FWIW

$ENZC $SAGA Sagaliam Acquisition Corp. filed a Third Party Complaint against GLD Sponsor Member, LLC and Daniel Gordon today. Here are all 10 pages of that complaint. 🔥

A thread...

Pages 1-4 pic.twitter.com/0tuaX2c1RL

— King of Prussia (@ImKingofPrussia) December 18, 2023

$ENZC $SAGA Sagaliam Acquisition Corp. filed a Third Party Complaint against GLD Sponsor Member, LLC and Daniel Gordon today. Here are all 10 pages of that complaint. 🔥

Pages 5-8 pic.twitter.com/0aG3wYnlCh

— King of Prussia (@ImKingofPrussia) December 18, 2023

$ENZC $SAGA Sagaliam Acquisition Corp. filed a Third Party Complaint against GLD Sponsor Member, LLC and Daniel Gordon today. Here are all 10 pages of that complaint. 🔥

Pages 9-10 pic.twitter.com/nfrILSUMtC

— King of Prussia (@ImKingofPrussia) December 18, 2023

$SAGA Punches Back 🤜

In this 3rd party complaint, #SAGA alledges Daniel Gordom has a serious conflict of interest where he would benefit from a failed deal, resulting in $1MM from the termination clause.

"Mr. Gordon stood to financially benefit from SAGA's breach of the… https://t.co/v5v3Q5RY4T pic.twitter.com/oWgx4xKdVS

— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) December 19, 2023

Yes, multiple violations.

But I believe that they will be fixed. Will take time, and they may have to start over again.

The stock is way oversold.

IMO - Buying at these levels should be rewarding if one is willing to take some risk of a further drop in price.

Same here.

Have all the time for things to evolve.

If I am correct, FDA approval may occur as early as spring or summer 2024.

Take it easy man. I can understand your excitement - the stock is up (and nicely) since a few days. Hopefully the gains accrued are not lost in the coming days, else we know how you are going to react.

I like the part that says the $54 price target is very conservative.

The analyst has been at it since a year. Nothing special about it. He will very likely have the same target after 6 months too.

need a dozen more preferably back to back.

Thanks to Missling, Bishop got a sample of 'Insomina' data (n=1)

This is not the first time he has mentioned that - 'sticking to milestones for the year xxxx'

Do not be surprised if he misses those milestone just like previous years.

To be frank with you, when there are extraordinary delays beyond one's control,thinking much does not help; rather it creates confusion and chaos.
So basically I have stopped thinking about AVXL.

12/1 is my personal line in the sand - has nothing to do with Missling (I can understand - he has to do his thing and let him do it the way he sees best).

Moreover, I do not have a big stake in AVXL that would affect me either way. I am already invested really big in another stock since sometime and used the same strategy that I used earlier in AVXL - to trade the swings - especially during the past 4 to 6 weeks - to get to zero cost - my DCA was 1.4s - did not sell call options this time as it is too dangerous given the impact the news may have, anytime it comes out).

The irony is despite spending time posting on this board (considering AVXL's performance YTD), I have had a lot better year compared to last year, which was good as I sold most of my AVXL shares. Might as well devote more time elsewhere.

To each their own.

Delay in data read-out is subject to interpretation.

February may be too late. Dec.1 is the timeline in the sand for me.

The next news related to AD is probably a few months away. Unless Anavex comes out with Rett EXCELLENCE news, the pps movement is going to be a repeat of history.

Today's news was a (first)step in the right direction.

Now we need to see how long it takes for the next step(s) and when that news will be published.

Then again stranger recent things have happened, like declaring a trial with an AD drug futile only to a year later revive it though subgroup analysis and subsequent success moving on to FDA approval, but not a commercial success.

Yes, Biogen has provided us with the blueprint. The bar for AD approval is set very low by the FDA. It is for Missling and team to present the data to the FDA and convince them why 2-73 should be approved for AD. Let us hope that they get it done in 2024 and if OLE data is going to be used, so be it.

Biogen and other players got their AD drug approved despite the fact that it hardly does much to benefit patients while they face the threat of brain bleeding and swelling. At least 2-73 does not have to deal with such serious adverse side effects. Combine that with AD approval and IMO, that should ensure commercial success, even if 2-73 is priced very close to Biogen's price.

I don't know.

Probably some Analyst can ask that question during Earnings CC.

Currently Rett-Timing Circus is playing out. AD and PDD have been relegated to the back benches.

My guess is they are waiting for OLE data. It should not take one year to crunch and munch over the complete data set, if it is not ambiguous or lacking in one form or the other - especially after the company declared at CTAD that both end points were met.

One could play the devil's advocate and come up with more than one stream of argument as to why there is a delay even after declaring success at CTAD.

A few more weeks for 2H of 2023 to be done and so many catalysts on the list.

There is hope. You will be 'AVXL green' someday next week if the progression continues (unless it is a fresh start all over again).

Thanks for the reminder. I got that memo long time back.

This is going back almost 3 years. Should make you feel good/bad/ugly as you read through - note the AVXL pps, DOW and S&P numbers too.

http://freepdfhosting.com/d83976a975.pdf

Not exactly a ringing endorsement from paid newsletter writer Tom Bishop. By the way, he hasn’t participated on an Anavex quarterly call in a very long time. Gee, I wonder why?

He is either tired of the delay or may be one last time - he is waiting - just like everyone, for Dec.31, 2023 - (read the last line).
Then he can write another article after exactly one year, on 1/2/2024.

https://www.moneyshow.com/articles/tptp2023-60140/top-picks-2023-anavex-avxl/

This is definitely not the time to sell (unless one wants to use it as tax loss selling). Most of them who sell will incur a loss - big or small.

Either buy or wait&watch.

Complaining does not change the situation.

Keeping it simple.

It has been below RS since $7 or did that escape you?

You have a point. May be I should have specified that current pps will tank by more than 50%

Current pps of $5.xx is < $1.5 before RS.

I am referring to current $5.xx dropping to 3.xx or even 2.xx making it pre-RS of < $0.90s or < $.75. ( over a period of few days). Not unheard of in biotechs - especially small/baby bio techs.

This only reinforces the high expectation about 2-73, as right now, PDD, PD, AD and Rett depend on it; or to put it in another way - how the current pps, even at these levels is solely propped up by 2-73 (alone) in various clinical trials (P2, P2/3) .

2-73 Rett EXCELLENCE success will be a vital cog in the success of Anavex. I am hoping that data is good enough to get FDA approval. ('Go Big or Go Home' time). The delay in AD Full Data read out has affected the whole chain of events leading to FDA approval and suddenly Rett is the crown jewel. Not many of us would have envisioned this before/after CTAD - it was assumed that there would be enough time and progress/development for FDA involvement with regard to AD, much before the Rett read out.

3-71 approval is many years away even if Phase 1 is skipped for new trials and P2 becomes the first step; (consider the chain of events - starting with planning a trial, to FDA approval).

ALL IMO.

I would like any Tom/Dick/Harry from the FDA to say it by approving it for Rett to begin with.

Mayo and Falconer says blarcamesine works, so it must be right. $6000 coming, WGT!!!
(I do not know and have no expertise in the field of biology or any related science-They may turn out to be right and if so everyone will be happy.)

$6000?

No big deal!!; After all, to get closer to the magic number, only need to move 3 decimal places to the right from where pps closed today.

The focus till EOY will soon shift to Catalysts for soon-to-be-last day of 2H of 2023.

If Blarcamesine works . .. . ..

At this stage in the game, it better work; else you will likely see the stock hit sub $2s, taking the pps back to pre-RS times . Let us hope it works fine and then some more.

This is when it is good to have an I-banker at the helm rather than a scientist

It is some comfort that Missling is qualified to wear multiple hats, given his educational and work backgrounds. We will have to wait and see if he can pull it off, given that it is his first rodeo.

A good scientist can be a good businessman (very common - to begin with get a MBA degree from elite school to add to the qualification), but it is extremely rare to find a good businessman who can be a good scientist. That being said, lawyers do not make good CEOs, especially of Biotech companies.

There are 35 business days left of 2023 to catch up on the Key Near Term Pipeline Updates, exactly zero of which have been accomplished to date. But its fine WGT!!!

Anavex Holiday Special, Greetings and Wishes - Memories of the yesteryear.

Dr. Jin could calculate this in his sleep

Someone needs to remind the guy ASAP that he needs to sleep.

Whatever happens - OK with me.

Have been buying regularly over the past few weeks.

Sincerely hope that he is doing OK and even if he is unwell, it is not AD.
(Seriously, nobody should get AD - at least in theory).

Not sure if the ex-FDA guy who is now no longer with AVXL had some health issues and decided to retire.

But at least we should be glad that Anavex stands firm and assured, that only 2 ex-FDA guys are required to fix that light bulb.

This is now a waiting game until the series of events unfold.

Yes sir, I had 500K shares (free shares via repeated selling call options and day trading), now have 2K shares only.
( First Bought first big tranche in 2015 - before the RS and then bought some more when it tanked after a couple of years).

Glad that I sold last year starting in Oct./Nov. and finally in Dec. and traded the whole thing one more time before investing the proceeds elsewhere - have a big position in couple of other stocks and also play options regularly - weeklies and 0DTE -SPY only.
(Paid the tax man his share of LT gains, yet still happier and wiser. But will admit that I was dumb enough not to sell when it hit 25+ in Feb. 2021).

CTAD anniversary is coming up and do not forget that we got the mother of all surprises.

Should I look forward to any surprise?
(May be that 'Surprise' will not make me richer but definitely won't make me poor - now that I have only 0.4% shares of AVXL compared to a year ago).

Let us see which one comes first - (in 2023)

$7 or Rett EXCELLENCE DATA or who knows, Name of MYSTERY DISEASE.

Some consolation - First from last.

For almost as long as he has been promising a new rare disease trial, which is three years now.

'Mystery' since then and now waiting for the latest 'Surprise'.